KORU Medical Systems (NASDAQ:KRMD) Posts Quarterly Earnings Results

KORU Medical Systems (NASDAQ:KRMD) posted its quarterly earnings results on Tuesday. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.04, FiscalAI reports. KORU Medical Systems had a negative return on equity of 10.63% and a negative net margin of 4.03%. The business had revenue of $11.57 million for the quarter, compared to the consensus estimate of $11.33 million.

Here are the key takeaways from KORU Medical Systems’ conference call:

• Q3 revenue grew 11% to $11.6 million, though growth slowed as expected amid international timing effects. On a normalized basis, domestic core revenue grew 10% and international core grew 23%; management expects high-teens growth in Q4.
• Profitability and margins improved: gross margin rose 500 basis points year over year to 65.2%, and the company reported its second consecutive quarter of positive net income, alongside progress in adjusted EBITDA.
• KORU raised its 2026 outlook: revenue guidance is now $48 million–$48.5 million, gross margin guidance is 63%–64%, and the company expects positive full-year adjusted EBITDA and year-end cash above $8 million.
• Commercial and product initiatives broaden potential growth: new distribution agreements in Europe and Africa, three specialty pharmacies dispensing KORU products for RYSTIGGO home administration, and progress on drug programs and the Freedom360 pump could expand reach, though several opportunities remain subject to partner timelines and regulatory review.

KORU Medical Systems Stock Down 2.2%

KRMD stock traded down $0.07 during trading on Tuesday, hitting $3.16. 207,913 shares of the company’s stock traded hands, compared to its average volume of 184,836. The firm has a market capitalization of $145.14 million, a P/E ratio of -79.00 and a beta of 0.47. KORU Medical Systems has a 1 year low of $2.86 and a 1 year high of $6.61. The business has a fifty day simple moving average of $3.12 and a two-hundred day simple moving average of $3.96.

Wall Street Analyst Weigh In

Several analysts recently weighed in on KRMD shares. Weiss Ratings downgraded KORU Medical Systems from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 29th. Wall Street Zen lowered shares of KORU Medical Systems from a “buy” rating to a “hold” rating in a research note on Saturday. Zacks Research cut shares of KORU Medical Systems from a “strong-buy” rating to a “hold” rating in a report on Friday, October 30th. Finally, Craig Hallum reiterated a “buy” rating and set a $6.00 target price on shares of KORU Medical Systems in a report on Thursday, August 6th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, KORU Medical Systems presently has an average rating of “Moderate Buy” and an average price target of $7.00.

Insiders Place Their Bets

In related news, insider Adam Kalbermatten bought 32,000 shares of the stock in a transaction on Tuesday, September 8th. The stock was bought at an average price of $3.16 per share, for a total transaction of $101,120.00. Following the completion of the acquisition, the insider directly owned 394,017 shares in the company, valued at approximately $1,245,093.72. This represents a 8.84% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 18.50% of the stock is currently owned by corporate insiders.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc. develops, manufactures and markets portable infusion systems and related accessories for the home and alternate-site infusion markets. The company’s products are designed to support the controlled delivery of specialty drugs, including subcutaneous immunoglobulin (SCIG) therapies, through ambulatory infusion systems. KORU’s principal product platform is the Freedom Syringe Infusion System, which includes ambulatory syringe pumps such as the Freedom60, FreedomEdge and FreedomIQ, along with flow-control tubing sets and other disposable components.